中医中药中医药抑制NSCLC对EGFR-TKI药物获得性耐药的研究进展

肺癌是最常见的恶性肿瘤之一,随着分子研究的不断发展,以表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)为靶点的肿瘤治疗——分子靶向治疗,成为了治疗非小细胞肺癌的新领域。虽然临床上一些对EGFR-TKI药物敏感的人群在控制病灶、改善症状方面都取得了很好的疗效,但多数患者在服药6～12个月后就会出现疾病进展,即产生获得性耐药。目前,多数患者在应用靶向药物治疗的同时也在服用中医药。靶向药物结合中医药已成为大多数晚期肺癌患者最佳的治疗模式。

Research Progress of Traditional Chinese Medicine Inhibition of NSCLC Acquired Drugs Resistance to EGFR-TKI

Lung cancer is one of the most common malignant tumors.With the advances in molecular studies,the epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)targeted tumor therapy-molecular targeted therapy has become a new field of treatment for non-small cell lung cancer.In clinical practice,the control of lesions and improvement of symptoms have achieved good results in EGFR-TKI drugs sensitive populations,however,disease progression was observed in the majority of patients after 6-12 months medication,i.e.acquired drug resistance occurred.At present,the majority of patients taking targeted drug therapy,also take Chinese herbal medicine.Combination of targeted therapy medicine has become the best treatment for most of the advanced lung cancer patients.